Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
The complexity of Alzheimer’s disease (AD) complicates the search for effective treatments. While the key roles of pathologically modified proteins has occupied a central role in hypotheses of the pathophysiology, less attention has been paid to the potential role for transition metals overload, subsequent oxidative stress, and tissue injury. The association of transition metals, the major focus heretofore iron and amyloid, the same can now be said for the likely pathogenic microtubular associated tau (MAPT). This review discusses the interplay between iron, pathologically modified tau and oxidative stress, and connects many related discoveries. Basic principles of the transition to pathological MAPT are discussed. Iron, its homeostatic mechanisms, the recently described phenomenon of ferroptosis and purported, although still controversial roles in AD are reviewed as well as considerations to overcome existing hurdles of iron-targeted therapeutic avenues that have been attempted in AD. We summarize the involvement of multiple pathological pathways at different disease stages of disease progression that supports the potential for a combinatorial treatment strategy targeting multiple factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Intrinsic peroxidase-like activity of ferromagnetic nanoparticles
Gao, L., Zhuang, J., Nie, L., Zhang, J., Zhang, Y., Gu, N., Wang, T., Feng, J., Yang, D., Perrett, S., et al. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.260 · Cited by 7,483 · cited 2×
“Artificial peroxidases have also been developed using metal oxide nanocrystalline materials (Fe3O4, CeO2, FeHPO) (Celardo et al., 2011; Gao et al., 2007; Zhang et al., 2014) that exhibit similar oxidative chemistry in the presence of hydrogen peroxide (Zhang et al.”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“, 2012) Aβ and α-synuclein that can easily form neurotoxic oligomers (Kayed et al., 2003; Lashuel et al., 2013).”
BackgroundClearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript PS19 (+)AP) in the cross-bred rats (Baker et al., 2011; Bussian et al., 2018).”
BackgroundOxidative DNA damage: mechanisms, mutation, and disease
Cooke, M. S., Evans, M. D., Dizdaroglu, M., & Lunec, J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0752rev · Cited by 3,245 · cited 1×
“Both hydroxyl and superoxide radicals can induce oxidative stress in cells by lipid, nucleic acid, or protein oxidation (Berlett and Stadtman, 1997; Cooke et al., 2003; Doll and Conrad, 2017).”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Second, experimental antibody therapies such as Aducanumab have shown that amyloid plaques can be cleared (Sevigny et al., 2016), though in the case of Aducanumab no therapeutic benefit emerged.”
BackgroundAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623 · cited 1×
“Cellular senescence has been associated with aging (van Deursen, 2014), and one underlying mechanism may involve a persistent DDR, that tends to be less efficient in post-mitotic neurons.”
BackgroundCellular senescence in aging and age-related disease: from mechanisms to therapy
Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363 · cited 4×
“Cellular senescence is a phenomenon first observed in cultured primary human cells by Hayflick and Moorehead, and is associated with aging and other causes, including pharmacological treatment where cells eventually cease to divide (Childs et al., 2015).”
BackgroundInfluential
Research works printed but not linked: 164
- Acosta-Cabronero, 2016, In vivo MRI mapping of brain iron deposition across the adult lifespan, J. Neurosci., 36, 364, 10.1523/JNEUROSCI.1907-15.2016 · DOI · Paper page
- Aguirre, 2012, The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1, Biometals, 25, 795, 10.1007/s10534-012-9525-y · DOI
- Ahmadi, 2017, Electrochemical studies of tau protein-iron interactions—potential implications for Alzheimer’s disease, Electrochim. Acta, 236, 384, 10.1016/j.electacta.2017.03.175 · DOI
- Alim, 2019, Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke, Cell, 177, 10.1016/j.cell.2019.03.032 · DOI · Paper page
- Alzheimer’s, 2012, 2012 Alzheimer’s disease facts and figures, Alzheimers Dement., 8, 131, 10.1016/j.jalz.2012.02.001 · DOI · Paper page
- Arif, 2014, Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of tau, J. Biol. Chem., 289, 27677, 10.1074/jbc.M114.565358 · DOI
- Ayala, 2014, Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal, Oxid. Med. Cell. Longev., 2014, 360438, 10.1155/2014/360438 · DOI · Paper page
- Ayton, 2018, Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study, J. Neurol. Neurosurg. Psychiatry, 89, 456, 10.1136/jnnp-2017-316551 · DOI · Paper page
- Ayton, 2017, Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline, Brain, 140, 2112, 10.1093/brain/awx137 · DOI · Paper page
- Bader, 2011, Single particle analysis of tau oligomer formation induced by metal ions and organic solvents, Biochem. Biophys. Res. Commun., 411, 190, 10.1016/j.bbrc.2011.06.135 · DOI
- Ballard, 2016, Dementia in Down’s syndrome, Lancet Neurol., 15, 622, 10.1016/S1474-4422(16)00063-6 · DOI · Paper page
- Bareggi, 2012, Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders, CNS Neurosci. Ther., 18, 41, 10.1111/j.1755-5949.2010.00231.x · DOI · Paper page
- Bautista, 2016, Iron-induced oxidative stress activates AKT and ERK1/2 and decreases Dyrk1B and PRMT1 in neuroblastoma SH-SY5Y cells, J. Trace Elem. Med. Biol., 34, 62, 10.1016/j.jtemb.2015.11.005 · DOI
- Belaidi, 2016, Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics, J. Neurochem., 139, 179, 10.1111/jnc.13425 · DOI · Paper page
- Berlett, 1997, Protein oxidation in aging, disease, and oxidative stress, J. Biol. Chem., 272, 20313, 10.1074/jbc.272.33.20313 · DOI · Paper page
- Bertrand, 2013, Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI, Neuroimage, 64, 693, 10.1016/j.neuroimage.2012.08.065 · DOI · Paper page
- Betrie, 2017, Evidences of a cardiovascular function for microtubule-associated protein tau, J. Alzheimer’s Dis., 56, 849, 10.3233/JAD-161093 · DOI
- Bhandary, 2012, An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases, Int. J. Mol. Sci., 14, 434, 10.3390/ijms14010434 · DOI · Paper page
- Billingsley, 1997, Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration, Biochem. J., 323, 577, 10.1042/bj3230577 · DOI · Paper page
- Bolognin, 2011, Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity, Int. J. Biochem. Cell Biol., 43, 877, 10.1016/j.biocel.2011.02.009 · DOI · Paper page
- Buée, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Brain Res. Rev., 33, 95, 10.1016/S0165-0173(00)00019-9 · DOI · Paper page
- Cardoso, 2017, Glutathione peroxidase 4: a new player in neurodegeneration?, Mol. Psychiatry, 22, 328, 10.1038/mp.2016.196 · DOI · Paper page
- Cascio, 2018, Azure C targets and modulates toxic tau oligomers, ACS Chem. Neurosci., 9, 1317, 10.1021/acschemneuro.7b00501 · DOI · Paper page
- Cecchi, 1999, Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer’s disease, Neurosci. Lett., 275, 152, 10.1016/S0304-3940(99)00751-X · DOI · Paper page
- Celardo, 2011, Pharmacological potential of cerium oxide nanoparticles, Nanoscale, 3, 1411, 10.1039/c0nr00875c · DOI · Paper page
- Chen, 2008, I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A, J. Biol. Chem., 283, 10513, 10.1074/jbc.M709852200 · DOI · Paper page
- Chiang, 2017, Relationships among cortical glutathione levels, brain amyloidosis, and memory in healthy older adults investigated in vivo with (1)H-MRS and Pittsburgh Compound-B PET, AJNR Am. J. Neuroradiol., 38, 1130, 10.3174/ajnr.A5143 · DOI · Paper page
- Chohan, 2006, Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine, FEBS Lett., 580, 3973, 10.1016/j.febslet.2006.06.021 · DOI · Paper page
- Cohen, 2004, GSK3 inhibitors: development and therapeutic potential, Nat. Rev. Drug Discov., 3, 479, 10.1038/nrd1415 · DOI · Paper page
- Cowan, 2012, What is the pathological significance of tau oligomers?, Biochem. Soc. Trans., 40, 693, 10.1042/BST20120135 · DOI · Paper page
- Derry, 2017, Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer’s disease, Brain, 140, 2066, 10.1093/brain/awx167 · DOI
- Dickson, 2010, Neuropathology of non-Alzheimer degenerative disorders, Int. J. Clin. Exp. Pathol., 3, 1
- Dineley, 2014, Insulin resistance in Alzheimer’s disease, Neurobiol. Dis., 72, 92, 10.1016/j.nbd.2014.09.001 · DOI · Paper page
- Dixon, 2012, Ferroptosis: an iron-dependent form of nonapoptotic cell death, Cell, 149, 1060, 10.1016/j.cell.2012.03.042 · DOI · Paper page
- Dlouhy, 2019, Fluorescence resonance energy transfer links membrane ferroportin, hephaestin but not ferroportin, amyloid precursor protein complex with iron efflux, J. Biol. Chem., 294, 4202, 10.1074/jbc.RA118.005142 · DOI
- Doll, 2017, Iron and ferroptosis: a still ill-defined liaison, IUBMB Life, 69, 423, 10.1002/iub.1616 · DOI · Paper page
- Dringen, 2000, Glutathione metabolism in brain: metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species, Eur. J. Biochem., 267, 4912, 10.1046/j.1432-1327.2000.01597.x · DOI · Paper page
- Duce, 2010, Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease, Cell, 142, 857, 10.1016/j.cell.2010.08.014 · DOI · Paper page
- Egaña, 2003, Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures, BioMetals, 16, 215, 10.1023/A:1020727218493 · DOI
- Eto, 2002, Brain hydrogen sulfide is severely decreased in Alzheimer’s disease, Biochem. Biophys. Res. Commun., 293, 1485, 10.1016/S0006-291X(02)00422-9 · DOI · Paper page
- Everett, 2014, Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer’s disease peptide beta-amyloid, Inorg. Chem., 53, 2803, 10.1021/ic402406g · DOI · Paper page
- Everett, 2014, Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer’s disease peptide beta-amyloid (1-42), J. R. Soc. Interface, 11, 10.1098/rsif.2014.0165 · DOI · Paper page
- Farina, 2017, Vitamin E for Alzheimer’s dementia and mild cognitive impairment, Cochrane Database Syst. Rev., 4, CD002854
- Ferrer, 2005, Current advances on different kinases involved in Tau Phosphorylation, and implications in Alzheimer’s disease and tauopathies, Curr. Alzheimer Res., 2, 3, 10.2174/1567205052772713 · DOI · Paper page
- Filograna, 2016, Anti-oxidants in Parkinson’s disease therapy: a critical point of view, Curr. Neuropharmacol., 14, 260, 10.2174/1570159X13666151030102718 · DOI · Paper page
- Finkelstein, 2017, The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease, Acta Neuropathol. Commun., 5, 53, 10.1186/s40478-017-0456-2 · DOI
- Flora, 2010, Chelation in metal intoxication, Int. J. Environ. Res. Public Health, 7, 2745, 10.3390/ijerph7072745 · DOI · Paper page
- Fu, 2014, Pharmacophore modeling, ensemble docking, virtual screening, and biological evaluation on glycogen synthase Kinase-3beta, Mol. Inform., 33, 610, 10.1002/minf.201400044 · DOI
- Galimberti, 2011, Disease-modifying treatments for Alzheimer’s disease, Ther. Adv. Neurol. Disord., 4, 203, 10.1177/1756285611404470 · DOI · Paper page
- Garrick, 2003, DMT1: a mammalian transporter for multiple metals, Biometals, 16, 41, 10.1023/A:1020702213099 · DOI · Paper page
- Gaschler, 2018, Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis, ACS Chem. Biol., 13, 1013, 10.1021/acschembio.8b00199 · DOI · Paper page
- George, 2011, The evolving classification of dementia: placing the DSM-V in a meaningful historical and cultural context and pondering the future of “Alzheimer’s”, Cult. Med. Psychiatry, 35, 417, 10.1007/s11013-011-9219-x · DOI
- Gerson, 2014, Characterization of tau oligomeric seeds in progressive supranuclear palsy, Acta Neuropathol. Commun., 2, 73, 10.1186/2051-5960-2-73 · DOI · Paper page
- Ghosh, 2014, Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species, Neurobiol. Aging, 35, 179, 10.1016/j.neurobiolaging.2013.06.023 · DOI
- Gong, 2000, Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain, J. Biol. Chem., 275, 5535, 10.1074/jbc.275.8.5535 · DOI · Paper page
- Haile, 1999, Regulation of genes of iron metabolism by the iron-response proteins, Am. J. Med. Sci., 318, 230, 10.1016/S0002-9629(15)40627-5 · DOI
- Hallgren, 1958, The effect of non-haemin iron in the human brain, J. Neurochem., 3, 41, 10.1111/j.1471-4159.1958.tb12607.x · DOI · Paper page
- Hampel, 2005, Apoptosis resistance of senescent human fibroblasts is correlated with the absence of nuclear IGFBP-3, Aging Cell, 4, 325, 10.1111/j.1474-9726.2005.00180.x · DOI · Paper page
- Hare, 2016, Iron and dopamine: a toxic couple, Brain, 139, 1026, 10.1093/brain/aww022 · DOI · Paper page
- Hare, 2015, Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturation, ACS Chem. Neurosci., 6, 398, 10.1021/cn5003557 · DOI · Paper page
- Harris, 2012, Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits, PLoS One, 7, e45881, 10.1371/journal.pone.0045881 · DOI · Paper page
- Hegde, 2009, Challenges associated with metal chelation therapy in Alzheimer’s disease, J. Alzheimers Dis., 17, 457, 10.3233/JAD-2009-1068 · DOI · Paper page
- Honarmand Ebrahimi, 2013, The amyloid precursor protein (APP) does not have a ferroxidase site in its E2 domain, PLoS One, 8, e72177, 10.1371/journal.pone.0072177 · DOI
- House, 2012, Aluminium, iron and copper in human brain tissues donated to the Medical Research Council’s Cognitive Function and Ageing Study, Metallomics, 4, 56, 10.1039/C1MT00139F · DOI · Paper page
- Iqbal, 2010, Alzheimer’s disease, a multifactorial disorder seeking multitherapies, Alzheimers Dement., 6, 420, 10.1016/j.jalz.2010.04.006 · DOI · Paper page
- Iqbal, 2013, Hyperphosphorylation-induced tau oligomers, Front. Neurol., 4, 112, 10.3389/fneur.2013.00112 · DOI · Paper page
- Jicha, 2009, Is passive immunization for Alzheimer’s disease’ alive and well’ or’ dead and buried’?, Expert Opin. Biol. Ther., 9, 481, 10.1517/14712590902828285 · DOI
- Kahklon, 2002, The labile iron pool: characterization, measurement, and participation in cellular processes, Free Radic. Biol. Med., 33, 1037
- Kanaan, 2011, Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases, J. Neurosci., 31, 9858, 10.1523/JNEUROSCI.0560-11.2011 · DOI · Paper page
- Kepp, 2012, Bioinorganic chemistry of Alzheimer’s disease, Chem. Rev., 112, 5193, 10.1021/cr300009x · DOI · Paper page
- Khatoon, 1994, Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains, FEBS Lett., 351, 80, 10.1016/0014-5793(94)00829-9 · DOI · Paper page
- Kim, 2015, Identification of disulfide cross-linked tau dimer responsible for tau propagation, Sci. Rep., 5, 15231, 10.1038/srep15231 · DOI · Paper page
- Kim, 2016, Six-transmembrane epithelial antigen of prostate 1 (STEAP1) has a single b heme and is capable of reducing metal ion complexes and oxygen, Biochemistry, 55, 6673, 10.1021/acs.biochem.6b00610 · DOI
- Kontoghiorghes, 2000, Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1), Transfus. Sci., 23, 211, 10.1016/S0955-3886(00)00089-8 · DOI
- Kontsekova, 2014, First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model, Alzheimers Res. Ther., 6, 44, 10.1186/alzrt278 · DOI · Paper page
- Köpke, 1993, Microtubule-associated protein tau: abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease, J. Biol. Chem., 268, 24374, 10.1016/S0021-9258(20)80536-5 · DOI · Paper page
- Köpke, 1993, Microtubule-associated protein tau: abnormal phosphorylatoin of a non-paired helical filament pool in Alzheimer disease, J. Biol. Chem., 268, 24374, 10.1016/S0021-9258(20)80536-5 · DOI · Paper page
- Kristinsson, 2012, Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies, Neuropsychiatr. Dis. Treat., 8, 515
- Kryscio, 2017, Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADViSE), JAMA Neurol., 74, 567, 10.1001/jamaneurol.2016.5778 · DOI · Paper page
- Lambert, 2010, The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention, Arch. Biochem. Biophys., 501, 65, 10.1016/j.abb.2010.06.013 · DOI · Paper page
- Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol., 7, 779, 10.1016/S1474-4422(08)70167-4 · DOI · Paper page
- Larson, 2004, Survival after initial diagnosis of Alzheimer disease, Ann. Intern. Med., 140, 501, 10.7326/0003-4819-140-7-200404060-00008 · DOI · Paper page
- Lashuel, 2013, The many faces of alpha-synuclein: from structure and toxicity to therapeutic target, Nat. Rev. Neurosci., 14, 38, 10.1038/nrn3406 · DOI · Paper page
- Lei, 2015, Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse, Neurobiol. Dis., 81, 168, 10.1016/j.nbd.2015.03.015 · DOI
- Lei, 2014, Motor and cognitive deficits in aged tau knockout mice in two background strains, Mol. Neurodegener., 9, 29, 10.1186/1750-1326-9-29 · DOI · Paper page
- Lloret, 2009, Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental, J. Alzheimers Dis., 17, 143, 10.3233/JAD-2009-1033 · DOI · Paper page
- Lodish, 2010, Endocrine side effects of broad-acting kinase inhibitors, Endocr. Relat. Cancer, 17, R233, 10.1677/ERC-10-0082 · DOI · Paper page
- Lovell, 1995, Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease, Neurology, 45, 1594, 10.1212/WNL.45.8.1594 · DOI · Paper page
- Lovell, 2000, Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer’s disease brain, Free Radic. Biol. Med., 28, 418, 10.1016/S0891-5849(99)00258-0 · DOI · Paper page
- Maeda, 2007, Granular tau oligomers as intermediates of tau filaments, Biochemistry, 46, 3856, 10.1021/bi061359o · DOI · Paper page
- Mandal, 2015, Brain glutathione levels—a novel biomarker for mild cognitive impairment and Alzheimer’s disease, Biol. Psychiatry, 78, 702, 10.1016/j.biopsych.2015.04.005 · DOI · Paper page
- Mander, 2017, Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer’s disease, Brain, 140, 2066, 10.1093/brain/awx174 · DOI
- Markesbery, 1997, Oxidative stress hypothesis in Alzheimer’s disease, Free Radic. Biol. Med., 23, 134, 10.1016/S0891-5849(96)00629-6 · DOI · Paper page
- Martin, 2010, Recent insights into protein phosphatase 2A structure and regulation: the reasons why PP2A is no longer considered as a lazy passive housekeeping enzyme, Biotechnol. Agron. Soc. Environ., 14, 243
- Martini, 2007, Hyperglycemia in acute ischemic stroke: a vascular perspective, J. Cereb. Blood Flow Metab., 27, 435, 10.1038/sj.jcbfm.9600355 · DOI · Paper page
- Matenia, 2009, The tau of MARK: a polarized view of the cytoskeleton, Trends Biochem. Sci., 34, 332, 10.1016/j.tibs.2009.03.008 · DOI · Paper page
- McCaddon, 2003, Alzheimer’s disease and total plasma aminothiols, Biol. Psychiatry, 53, 254, 10.1016/S0006-3223(02)01451-8 · DOI
- McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease, Neurology, 2, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- McLachlan, 1991, Intramuscular desferrioxamine in patients with Alzheimer’s disease, Lancet, 337, 1304, 10.1016/0140-6736(91)92978-B · DOI · Paper page
- Medina, 2016, New features about tau function and dysfunction, Biomolecules, 6, 10.3390/biom6020021 · DOI · Paper page
- Mitra, 2014, Revisiting metal toxicity in neurodegenerative diseases and stroke: therapeutic potential, Neurol. Res. Ther., 1
- Mohamed, 2013, Tau-derived-hexapeptide 306VQIVYK311 aggregation inhibitors: nitrocatechol moiety as a pharmacophore in drug design, ACS Chem. Neurosci., 4, 1559, 10.1021/cn400151a · DOI
- Moos, 2007, Iron trafficking inside the brain, J. Neurochem., 103, 1730, 10.1111/j.1471-4159.2007.04976.x · DOI · Paper page
- Mun, 2010, Identification of CD44 as a senescence-induced cell adhesion gene responsible for the enhanced monocyte recruitment to senescent endothelial cells, Am. J. Physiol. Heart Circ. Physiol., 298, H2102, 10.1152/ajpheart.00835.2009 · DOI · Paper page
- Murayama, 1999, Interaction of aluminum with PHFτ in Alzheimer’s disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method, Am. J. Pathol., 155, 877, 10.1016/S0002-9440(10)65187-5 · DOI
- Nielsen, 2003, Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases, Br. J. Haematol., 123, 952, 10.1046/j.1365-2141.2003.04708.x · DOI
- Novak, 2017, Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial, Lancet Neurol., 16, 123, 10.1016/S1474-4422(16)30331-3 · DOI · Paper page
- Nubling, 2012, Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level, Mol. Neurodegener., 7, 35, 10.1186/1750-1326-7-35 · DOI · Paper page
- O’Callaghan, 2017, Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer’s disease, Neuroimage, 159, 334, 10.1016/j.neuroimage.2017.08.003 · DOI
- Petry, 2014, Specificity of anti-tau antibodies when analyzing mice models of Alzheimer’s disease: problems and solutions, PLoS One, 9, e94251, 10.1371/journal.pone.0094251 · DOI · Paper page
- Plascencia-Villa, 2016, High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer’s disease, Sci. Rep., 6, 24873, 10.1038/srep24873 · DOI · Paper page
- Porter, 2005, Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use, Ann. N. Y. Acad. Sci., 1054, 155, 10.1196/annals.1345.018 · DOI · Paper page
- Pradeepkiran, 2019, Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer’s disease, Cells, 8, 10.3390/cells8030260 · DOI
- Prasanthi, 2012, Deferiprone reduces amyloid-beta and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet, J. Alzheimers Dis., 30, 167, 10.3233/JAD-2012-111346 · DOI · Paper page
- Raha, 2013, The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease, Acta Neuropathol. Commun., 1, 1, 10.1186/2051-5960-1-55 · DOI · Paper page
- Ramos, 2014, Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes, J. Trace Elem. Med. Biol., 28, 13, 10.1016/j.jtemb.2013.08.001 · DOI · Paper page
- Rane, 2019, An acetylation mimicking mutation, K274Q, in tau imparts neurotoxicity by enhancing tau aggregation and inhibiting tubulin polymerization, Biochem. J., 476, 1401, 10.1042/BCJ20190042 · DOI · Paper page
- Rickle, 2004, Akt activity in Alzheimer’s disease and other neurodegenerative disorders, Neurochemistry, 15, 955
- Rietjens, 2002, The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids, Environ. Toxicol. Pharmacol., 11, 321, 10.1016/S1382-6689(02)00003-0 · DOI · Paper page
- Robinson, 2009, Hemin toxicity: a preventable source of brain damage following hemorrhagic stroke, Redox Rep., 14, 228, 10.1179/135100009X12525712409931 · DOI · Paper page
- Salgado, 2017, The reactivity and reaction pathway of Fenton reactions driven by substituted 1,2-dihydroxybenzenes, Environ. Sci. Technol., 51, 3687, 10.1021/acs.est.6b05388 · DOI
- Samuel, 2014, Hydrophilic carbon clusters as therapeutic, high-capacity antioxidants, Trends Biotechnol., 32, 501, 10.1016/j.tibtech.2014.08.005 · DOI
- Sayre, 2000, In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals, J. Neurochem., 74, 270, 10.1046/j.1471-4159.2000.0740270.x · DOI · Paper page
- Schrag, 2011, Iron, zinc and copper in the Alzheimer’s disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion, Prog. Neurobiol., 94, 296, 10.1016/j.pneurobio.2011.05.001 · DOI · Paper page
- Schuff, 2009, MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers, Brain, 132, 1067, 10.1093/brain/awp007 · DOI · Paper page
- Sharma, 2018, Advances in multi-functional ligands and the need for metal-related pharmacology for the management of Alzheimer disease, Front. Pharmacol., 9, 1247, 10.3389/fphar.2018.01247 · DOI · Paper page
- Shin, 2003, A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease, Brain Res., 961, 139, 10.1016/S0006-8993(02)03893-3 · DOI
- Shin, 1994, Aluminum modifies the properties of Alzheimer’s disease PHFT proteins in vivo and in vitro, J. Neurosci., 14, 7221, 10.1523/JNEUROSCI.14-11-07221.1994 · DOI
- Smith, 1997, Iron accumulation in Alzheimer disease is a source of redox-generated free radicals, Proc. Natl. Acad. Sci. U. S. A., 94, 9866, 10.1073/pnas.94.18.9866 · DOI · Paper page
- Soeda, 2015, Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups, Nat. Commun., 6, 10216, 10.1038/ncomms10216 · DOI · Paper page
- Stamer, 2002, Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, J. Cell Biol., 156, 1051, 10.1083/jcb.200108057 · DOI · Paper page
- Stankowski, 2012, Ironing out tau’s role in Parkinsonism, Nat. Med., 18, 197, 10.1038/nm.2668 · DOI
- Stoothoff, 2005, Tau phosphorylation: physiological and pathological consequences, Biochim. Biophys. Acta, 1739, 280, 10.1016/j.bbadis.2004.06.017 · DOI · Paper page
- Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil, JAMA, 291, 317, 10.1001/jama.291.3.317 · DOI · Paper page
- Telling, 2017, Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer’s disease, Cell Chem. Biol., 24, 10.1016/j.chembiol.2017.07.014 · DOI · Paper page
- Uranga, 2009, Iron-induced oxidative injury differentially regulates PI3K/Akt/GSK3beta pathway in synaptic endings from adult and aged rats, Toxicol. Sci., 111, 331, 10.1093/toxsci/kfp152 · DOI
- van Bergen, 2016, Colocalization of cerebral iron with amyloid beta in mild cognitive impairment, Sci. Rep., 6, 35514, 10.1038/srep35514 · DOI · Paper page
- Veinbergs, 2000, Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice, Eur. J. Neurosci., 12, 4541
- Vossel, 2010, Tau reduction prevents Ab-induced defects in axonal transport, Science, 330, 198, 10.1126/science.1194653 · DOI · Paper page
- Wallin, 2018, The neuronal tau protein blocks in vitro fibrillation of the amyloid-beta (Abeta) peptide at the oligomeric stage, J. Am. Chem. Soc., 140, 8138, 10.1021/jacs.7b13623 · DOI
- Wang, 2012, Iron enhances the neurotoxicity of amyloid beta, Transl. Stroke Res., 3, 107, 10.1007/s12975-011-0099-8 · DOI
- Wang, 2010, Structural basis for certain naturally occurring bioflavonoids to function as reducing co-substrates of cyclooxygenase I and II, PLoS One, 5, e12316, 10.1371/journal.pone.0012316 · DOI
- Wang, 2017, Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: is damage response signaling a potential therapeutic target?, Mech. Ageing Dev., 161, 163, 10.1016/j.mad.2016.09.005 · DOI
- Wang, 2017, Tau interactome mapping based identification of Otub1 as tau deubiquitinase involved in accumulation of pathological tau forms in vitro and in vivo, Acta Neuropathol., 133, 731, 10.1007/s00401-016-1663-9 · DOI · Paper page
- Ward, 2014, The role of iron in brain ageing and neurodegenerative disorders, Lancet Neurol., 13, 1045, 10.1016/S1474-4422(14)70117-6 · DOI · Paper page
- Ward, 2012, Tau oligomers and tau toxicity in neurodegenerative disease, Biochem. Soc. Trans., 40, 667, 10.1042/BST20120134 · DOI · Paper page
- Waxman, 2011, Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau, J. Neurosci., 31, 7604, 10.1523/JNEUROSCI.0297-11.2011 · DOI · Paper page
- Webb, 1973, Spectroscopic and magnetic studies of iron(111) phosvitins, Biochemistry, 12
- Weinreb, 2009, Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties, Genes Nutr., 4, 283, 10.1007/s12263-009-0143-4 · DOI · Paper page
- Weinshenker, 2018, Long road to ruin: noradrenergic dysfunction in neurodegenerative disease, Trends Neurosci., 41, 211, 10.1016/j.tins.2018.01.010 · DOI · Paper page
- West, 2017, Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies, J. Prev. Alzheimers Dis., 4, 236
- Wilkinson, 2004, Protein disulfide isomerase, Biochim. Biophys. Acta, 1699, 35, 10.1016/S1570-9639(04)00063-9 · doi:10.1016/s1570-9639(04)00063-9 · Paper page
- Wischik, 2014, Tau-aggregation inhibitor therapy for Alzheimer’s disease, Biochem. Pharmacol., 88, 529, 10.1016/j.bcp.2013.12.008 · DOI · Paper page
- Wong, 1997, Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig, Biometals, 10, 247, 10.1023/A:1018312113969 · doi:10.1023/a:1018312113969
- Wong, 2014, Beta-amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin, PLoS One, 9, e114174, 10.1371/journal.pone.0114174 · DOI · Paper page
- Yang, 2007, Deferasirox: a review of its use in the management of transfusional chronic iron overload, Drugs, 67, 2211, 10.2165/00003495-200767150-00007 · DOI
- Yoo, 2010, Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer’s disease, Antioxid. Redox Signal., 12, 819, 10.1089/ars.2009.2891 · DOI · Paper page
- Yuzwa, 2012, Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation, Nat. Chem. Biol., 8, 393, 10.1038/nchembio.797 · DOI · Paper page
- Zecca, 2001, Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour, Mol. Pathol., 54, 414
- Zhang, 2010, Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner, Brain Res., 1345, 176, 10.1016/j.brainres.2010.04.074 · DOI
- Zhang, 2014, Synthesis of hierarchical iron hydrogen phosphate crystal as a robust peroxidase mimic for stable H(2)O(2) detection, ACS Appl. Mater. Interfaces, 6, 14433, 10.1021/am503708a · DOI
- Zhang, 2018, Alpha-lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice, Redox Biol., 14, 535, 10.1016/j.redox.2017.11.001 · DOI · Paper page
- Zhang, 2017, Selenomethionine mitigates cognitive decline by targeting both tau hyperphosphorylation and autophagic clearance in an Alzheimer’s disease mouse model, J. Neurosci., 37, 2449, 10.1523/JNEUROSCI.3229-16.2017 · DOI · Paper page
- Zilka, 2017, On the mechanism of cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death, ACS Cent. Sci., 3, 232, 10.1021/acscentsci.7b00028 · DOI · Paper page
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Contribution of ferroptosis and GPX4’s dual functions to osteoarthritis progression
Miao, Y., Chen, Y., Xue, F., Liu, K., Zhu, B., Gao, J., Yin, J., Zhang, C., & Li, G. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103847 · Cited by 483
Interaction between macrophages and ferroptosis
Yang, Y., Wang, Y., Guo, L., Gao, W., Tang, T.-L., & Yan, M. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04775-z · Cited by 385
Metadata
- Authors
- Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 184
- Pages
- 101716
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2980072878
- Cited by
- 140
- References
- 90
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Welch Foundation
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. https://app.cochat.ai/papers/10.1016/j.pneurobio.2019.101716
- The paper
- Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A. (2020). Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2019.101716
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.